Please login to the form below
CGRP
This page shows the latest CGRP news and features for those working in and with pharma, biotech and healthcare.
Pfizer to acquire Biohaven in deal worth over $11bn
Medicine. “Nurtec ODT, which is already the number one prescribed migraine medicine in its class in the US, coupled with Biohaven’s CGRP pipeline, offers hope for patients suffering from migraine
Latest news
-
Pfizer snaps up Biohaven’s migraine drug for $1.24bn
It is the ‘first and only’ oral drug to inhibit calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine and currently accounts for more than ... The drug, originally developed at Bristol Myers
-
Biohaven gets FDA approval for migraine drug Nurtec ODT
Biohaven Pharma has become the second drugmaker to bring an oral CGRP inhibitor to the US market for acute migraine, after the US Food and Drug Administration (FDA) approved its Nurtec ... Both the oral CGRP inhibitors have benefited from a collaboration
-
Modest meeting sees only two drugs recommended by CHMP
The FDA approved Emgality for use in this indication back in June last year, a win for Lilly that meant Emgality became the first CGRP inhibitor indicated for use in reducing
-
Lundbeck gets US approval for migraine drug at heart of Alder takeover
US regulator clears CGRP inhibitor under Vyepti trade name. Lundbeck has the payoff it was looking for from its acquisition of Alder Biopharma last year, claiming FDA approval for migraine prevention ... All the new CGRP brands have been affected by
-
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Its closest competitor is Allergan’s Ubrelvy (ubrogepant) – an oral CGRP inhibitor which also has FDA approval in the treatment of acute migraine, with or without aura. ... Analysts have suggested that Allergan’s oral CGRP franchise – which also
More from news
Approximately 6 fully matching, plus 40 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
1. Rimegepant from BioHaven Pharmaceuticals is an antagonist of calcitonin gene-related peptide (CGRP), recently approved in the US for the acute treatment of migraine, with prevention trials also ongoing. ... Allergan’s Ubrelvy is the only other oral
-
Deal Watch January 2018
Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... licence agreement in January with respect to calcitonin gene-related peptide
-
The good, the bad and the ugly
Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.
-
Deal Watch November 2015
455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.
-
Pharma deals in July 2015
related peptide (CGRP) receptor antagonist programme with the lead product at the end of phase II for treatment of migraine. ... 293. Merck / Allergan. Acquisition of R&D. Oral CGRP compounds (lead Phase 2) for migraine.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
